Lineage Cell Therapeutics has been granted a patent for a method of generating human retinal pigment epithelium (RPE) cells with specific characteristics. The method involves culturing pluripotent stem cells in specific conditions to generate RPE cells that co-express certain proteins. GlobalData’s report on Lineage Cell Therapeutics gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
According to GlobalData’s company profile on Lineage Cell Therapeutics, Embryonic stem cell culturing was a key innovation area identified from patents. Lineage Cell Therapeutics's grant share as of May 2024 was 36%. Grant share is based on the ratio of number of grants to total number of patents.
Generating human rpe cells with specific protein expression
A recently granted patent (Publication Number: US11987810B2) discloses a method for generating retinal pigment epithelium (RPE) cells from human pluripotent stem cells. The method involves a series of steps including culturing the stem cells in a medium containing nicotinamide, devoid of Activin A, followed by further culturing in a medium with Activin A and nicotinamide to differentiate the cells towards an RPE lineage. Subsequent culturing in nicotinamide-containing medium leads to the generation of RPE cells. The process is carried out under low oxygen conditions, with specific markers indicating successful differentiation of RPE cells.
Furthermore, the patent claims detail additional steps such as expanding the RPE cells, culturing in suspension, or on an extracellular matrix, and selecting polygonal cells post differentiation. The method also specifies the use of embryonic stem cells, prior propagation conditions, and oxygen levels during different stages of the process. The patent highlights the importance of co-expression of specific proteins, PMEL17 and CRALBP, as indicators of successful RPE cell generation. The method provides a detailed protocol for efficiently generating RPE cells from human pluripotent stem cells, offering potential applications in regenerative medicine and research related to retinal diseases.
To know more about GlobalData’s detailed insights on Lineage Cell Therapeutics, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies across the world’s largest industries.
